Watson Pharmaceuticals Inc. on Wednesday presented updated information on the effectiveness of its experimental topical gel to treat overactive bladder syndrome.
New data from three studies of men and women showed the gel remained effective after both showering and the application of sunscreen.
A prior study by Watson showed the gel, which contains oxybutynin chloride, was more effective at controlling overactive bladder than placebo, based on fewer incontinence episodes reported by patients.
Shares of Watson Pharmaceuticals fell 15 cents to $25.45 in morning trading.
New data from three studies of men and women showed the gel remained effective after both showering and the application of sunscreen.
A prior study by Watson showed the gel, which contains oxybutynin chloride, was more effective at controlling overactive bladder than placebo, based on fewer incontinence episodes reported by patients.
Shares of Watson Pharmaceuticals fell 15 cents to $25.45 in morning trading.
0 comments:
Post a Comment